Resistance to temozolomide in the treatment of glioblastoma (GBM) is related to the upregulation of O6-methylguanine-DNA methyltransferase (MGMT), whereas the expression of MGMT in tumor cells is negatively regulated by WT p53 [82–84]. The gene discussed is MGMT; the disease is glioblastoma.